ChAdOx1 NCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis

Overview

Journal Vaccines (Basel)

Date 2022 Jun 24

PMID 35746567

Authors

Wisit Prasithsirikul

Tanawin Nopsopon

Phanupong Phutrakool

Pawita Suwanwattana

Piyawat Kantagowit

Wannarat Pongpirul

Anan Jongkaewwattana

Krit Pongpirul

Affiliations

Soon will be listed here.

Abstract

Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) were found to have a decreased immune response following mRNA COVID-19 immunization. ChAdOx1 nCoV-19 was a promising COVID-19 vaccine that performed well in the general population, but the evidence on immunogenicity in ESRD with HD patients was limited. Moreover, the immunological response to COVID-19 infection was inconclusive in patients with ESRD and HD. The aim of this study was to investigate the immunogenicity of ChAdOx1 nCoV-19 vaccination and the immunological response after COVID-19 infection in ESRD patients with HD. The blood samples were obtained at baseline, 1-month, and 3-month follow-up after each shot or recovery. All participants were measured for anti-spike IgG by the ELISA method, using Euroimmun. This study found a significant increase in anti-spike IgG after 1 month of two-shot ChAdOx1 nCoV-19 vaccination, followed by a significant decrease after 3 months. On the other hand, the anti-spike IgG was maintained in the post-recovery group. There was no significant difference in the change of anti-spike IgG between the one-shot ChAdOx1 nCoV-19-vaccinated and post-recovery groups for both 1-month and 3-month follow-ups. The seroconversion rate for the vaccinated group was 60.32% at 1 month after one-shot vaccination and slightly dropped to 58.73% at the 3-month follow-up, then was 92.06% at 1 month after two-shot vaccination and reduced to 82.26% at the 3-month follow-up. For the recovered group, the seroconversion rate was 95.65% at 1 month post-recovery and 92.50% at 3-month follow-up. This study demonstrated the immunogenicity of two-dose ChAdOx1 nCoV-19 in ESRD patients with HD for humoral immunity. After COVID-19 infection, the humoral immune response was strong and could be maintained for at least three months.

Citing Articles

18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income setting.

Karunathilake R, Kumara R, Karunathilaka A, Wazil A, Nanayakkara N, Bandara C BMC Nephrol. 2024; 25(1):176.

PMID: 38778281 PMC: 11112903. DOI: 10.1186/s12882-024-03599-7.

Long-term evaluation of the seroprevalence of SARS-CoV-2 IgG and IgM antibodies in recovered patients: a meta-analysis.

Li Q, Chen L, Li F, He A BMC Infect Dis. 2023; 23(1):444.

PMID: 37393304 PMC: 10314509. DOI: 10.1186/s12879-023-08425-3.

Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort.

Clavero R, Parra-Lucares A, Mendez-Valdes G, Villa E, Bravo K, Mondaca E Vaccines (Basel). 2022; 10(9).

PMID: 36146621 PMC: 9503801. DOI: 10.3390/vaccines10091542.

SARS-CoV-2 Vaccination: What Can We Expect Now?.

Meurens F, Renois F, Bouin A, Zhu J Vaccines (Basel). 2022; 10(7).

PMID: 35891257 PMC: 9319792. DOI: 10.3390/vaccines10071093.

References

Rosati M, Terpos E, Ntanasis-Stathopoulos I, Agarwal M, Bear J, Burns R . Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Front Immunol. 2021; 12:793953. PMC: 8660679. DOI: 10.3389/fimmu.2021.793953. View

Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E . The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int. 2021; 100(4):928-936. PMC: 8286235. DOI: 10.1016/j.kint.2021.07.005. View

Barrett J, Belij-Rammerstorfer S, Dold C, Ewer K, Folegatti P, Gilbride C . Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2020; 27(2):279-288. DOI: 10.1038/s41591-020-01179-4. View

Bertrand D, Hamzaoui M, Lemee V, Lamulle J, Hanoy M, Laurent C . Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. J Am Soc Nephrol. 2021; 32(9):2147-2152. PMC: 8729845. DOI: 10.1681/ASN.2021040480. View

Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S . Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transplant. 2021; 36(9):1709-1716. PMC: 8194560. DOI: 10.1093/ndt/gfab179. View

Speer C, Goth D, Benning L, Buylaert M, Schaier M, Grenz J . Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clin J Am Soc Nephrol. 2021; 16(7):1073-1082. PMC: 8425619. DOI: 10.2215/CJN.03700321. View

Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

Jahn M, Korth J, Dorsch O, Anastasiou O, Sorge-Hadicke B, Tyczynski B . Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. Vaccines (Basel). 2021; 9(4). PMC: 8070660. DOI: 10.3390/vaccines9040360. View

Wheatley A, Juno J, Wang J, Selva K, Reynaldi A, Tan H . Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021; 12(1):1162. PMC: 7896046. DOI: 10.1038/s41467-021-21444-5. View

10.

McGrath L, Kshirsagar A, Cole S, Wang L, Weber D, Sturmer T . Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med. 2012; 172(7):548-54. PMC: 4082376. DOI: 10.1001/archinternmed.2011.2238. View

11.

Tretyn A, Szczepanek J, Skorupa M, Jarkiewicz-Tretyn J, Sandomierz D, Dejewska J . Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination. Cells. 2021; 10(8). PMC: 8391384. DOI: 10.3390/cells10081952. View

12.

Ziemba R, Campbell K, Yang T, Schaeffer S, Mayo K, McGann P . Excess Death Estimates in Patients with End-Stage Renal Disease - United States, February-August 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(22):825-829. PMC: 8174675. DOI: 10.15585/mmwr.mm7022e2. View

13.

Broseta J, Rodriguez-Espinosa D, Rodriguez N, Mosquera M, Marcos M, Egri N . Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. Am J Kidney Dis. 2021; 78(4):571-581. PMC: 8223037. DOI: 10.1053/j.ajkd.2021.06.002. View

14.

Ewer K, Barrett J, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R . T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020; 27(2):270-278. DOI: 10.1038/s41591-020-01194-5. View

15.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

16.

Nopsopon T, Kittrakulrat J, Takkavatakarn K, Eiamsitrakoon T, Kanjanabuch T, Pongpirul K . Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2021; 15(6):e0009156. PMC: 8232454. DOI: 10.1371/journal.pntd.0009156. View

17.

Rincon-Arevalo H, Choi M, Stefanski A, Halleck F, Weber U, Szelinski F . Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021; 6(60). DOI: 10.1126/sciimmunol.abj1031. View

18.

Mastalerz-Migas A, Steciwko A, Brydak L . Immune response to influenza vaccine in hemodialysis patients with chronic renal failure. Adv Exp Med Biol. 2012; 756:285-90. DOI: 10.1007/978-94-007-4549-0_35. View

19.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

20.

Lesny P, Anderson M, Cloherty G, Stec M, Haase-Fielitz A, Haarhaus M . Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study. J Nephrol. 2021; 34(4):975-983. PMC: 8164063. DOI: 10.1007/s40620-021-01076-0. View